REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

5 Dec 2013 07:00

RNS Number : 7365U
Sopheon PLC
05 December 2013
 



FOR IMMEDIATE RELEASE

5 December 2013

 

 

SOPHEON PLC

 

CORPORATE UPDATE

 

 

Sopheon plc ("Sopheon" or "the Group") issues an update on certain corporate matters.

 

Restructuring

 

The Group's capital restructuring was initiated earlier this year following shareholder approval in June, and was made up of two elements; a capital reorganization followed by a capital reduction.

 

The capital reorganization comprised a share consolidation implemented through a two-step process involving a 10,000:1 share consolidation, followed by a 1:500 share subdivision one week later. This procedure reduced the number of shares in issue by a ratio of 20. It also reduced the number of shareholders on the Company's UK share register from approximately 4,000 to just over 200. By the same token shareholders in the Dutch system were expected to fall from over 7,000 to under 2,000. However, as previously noted, we understand that the reduction was not correctly processed by certain brokers in the Netherlands. We believe this means the Dutch shareholder count may have reduced to around 5,000. We have made enquiries and representations in the Netherlands but the board has found the responses unsatisfactory. Accordingly, the board is actively considering the possibility of seeking shareholder approval for a fresh 500:1 consolidation during the first quarter of 2014. We will continue to assess the alternatives, and will update shareholders in due course. 

 

The second element of the restructuring, the capital reduction had the objective of reducing the deficit on the Group's accumulated reserves. This has now been approved by the court, and a certificate has been issued by the Registrar of Companies.

 

Chairman Barry Mence said: "It's good to see the capital reduction concluded, a further milestone in the corporate changes that we started with last year's transfer from Euronext to Alternext. We will continue to assess how to handle the apparent misprocessing of the consolidation procedure by in the Netherlands system, and will revert to shareholders once we have decided our approach"

 

Financing

 

As we have indicated in previous announcements, the Group's facilities with BlueCrest Capital ("BlueCrest") will expire on maturity of the term loan in March 2014. The balances outstanding on the medium-term debt and revolving credit facility are currently $0.36m and $0.40m respectively. The term debt is being paid down monthly and the revolving facility is used to manage short term currency requirements. BlueCrest is winding down its lending business, and therefore these facilities will not be renewed. The board has been exploring replacement facilities and has signed a provisional term sheet in this regard with a major US bank. We will announce further details as and when they become formalized.

 

In addition, the Company has agreed terms with GEM Global Yield Fund Limited ("GEM") to extend the Group's equity line of credit facility for a further two year period up to 23 December 2015. This is the fifth such extension, and the terms of the facility are otherwise unchanged. Sopheon retains full control of the amount and timing of any subscription under the equity line and will be under no obligation to use the facility at any point. Since inception, the facility has been used to raise working capital on one occasion in March 2004, leaving approximately 90% of the original €10m facility available under the extended agreement.

 

CFO Arif Karimjee said: "We have a long standing relationship with GEM, and the equity line is an important component of Sopheon's financing structure. We have no immediate intention of using the facility, however we are delighted to be extending for an additional two years."

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

About GEM

Global Emerging Markets Limited was founded in 1991. GEM is a $3.4b investment group having completed 305 transactions in 65 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. GEM's funds include: CITIC/GEM Fund; VC Bank/GEM Mena Fund*; Kinderhook; GEM Global Yield Fund; GEM India Advisors, BLOM GEM Opportunities Fund and GEM Brazil PE Fund (*GEM exited both its LP and GP stakes in Q1 2010). For more information, please visit www.gemny.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMGZVDVGFZM
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.